96 related articles for article (PubMed ID: 19666910)
1. Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies--the effect on podocytes.
Nemeth Z; Kokeny G; Godo M; Mózes M; Rosivall L; Gross ML; Ritz E; Hamar P
Nephrol Dial Transplant; 2009 Dec; 24(12):3640-51. PubMed ID: 19666910
[TBL] [Abstract][Full Text] [Related]
2. Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination.
Piecha G; Koleganova N; Gross ML; Geldyyev A; Adamczak M; Ritz E
Am J Physiol Renal Physiol; 2008 Jul; 295(1):F137-44. PubMed ID: 18434388
[TBL] [Abstract][Full Text] [Related]
3. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure.
Amann K; Nichols C; Tornig J; Schwarz U; Zeier M; Mall G; Ritz E
Nephrol Dial Transplant; 1996 Jun; 11(6):1003-11. PubMed ID: 8671960
[TBL] [Abstract][Full Text] [Related]
4. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
5. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat.
Kuhlmann A; Haas CS; Gross ML; Reulbach U; Holzinger M; Schwarz U; Ritz E; Amann K
Am J Physiol Renal Physiol; 2004 Mar; 286(3):F526-33. PubMed ID: 14600034
[TBL] [Abstract][Full Text] [Related]
6. The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model.
Hamar P; Kokeny G; Liptak P; Krtil J; Adamczak M; Amann K; Ritz E; Gross ML
Nephron Exp Nephrol; 2007; 105(4):e124-36. PubMed ID: 17347582
[TBL] [Abstract][Full Text] [Related]
7. Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species.
van den Hoven MJ; Waanders F; Rops AL; Kramer AB; van Goor H; Berden JH; Navis G; van der Vlag J
Nephrol Dial Transplant; 2009 Sep; 24(9):2637-45. PubMed ID: 19429930
[TBL] [Abstract][Full Text] [Related]
8. [Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure].
Ciechanowicz A
Ann Acad Med Stetin; 1999; Suppl 52():1-93. PubMed ID: 10589103
[TBL] [Abstract][Full Text] [Related]
9. Effects of combined endothelin and angiotensin II antagonism on growth factor-induced proliferation of vascular smooth muscle cells isolated from uremic rats.
Wolf SC; Sauter G; Risler T; Brehm BR
Ren Fail; 2005; 27(4):465-74. PubMed ID: 16060137
[TBL] [Abstract][Full Text] [Related]
10. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.
Gagliardini E; Corna D; Zoja C; Sangalli F; Carrara F; Rossi M; Conti S; Rottoli D; Longaretti L; Remuzzi A; Remuzzi G; Benigni A
Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1448-56. PubMed ID: 19675181
[TBL] [Abstract][Full Text] [Related]
11. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
Sato A; Hayashi K; Saruta T
Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Bauersachs J; Fraccarollo D
Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
[TBL] [Abstract][Full Text] [Related]
13. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
Ogawa S; Takeuchi K; Mori T; Nako K; Ito S
Clin Exp Pharmacol Physiol; 2006; 33(5-6):477-9. PubMed ID: 16700881
[TBL] [Abstract][Full Text] [Related]
15. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.
Toyonaga J; Tsuruya K; Ikeda H; Noguchi H; Yotsueda H; Fujisaki K; Hirakawa M; Taniguchi M; Masutani K; Iida M
Nephrol Dial Transplant; 2011 Aug; 26(8):2475-84. PubMed ID: 21220752
[TBL] [Abstract][Full Text] [Related]
16. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats.
Adamczak M; Gross ML; Krtil J; Koch A; Tyralla K; Amann K; Ritz E
J Am Soc Nephrol; 2003 Nov; 14(11):2833-42. PubMed ID: 14569093
[TBL] [Abstract][Full Text] [Related]
17. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
Chrysostomou A; Pedagogos E; MacGregor L; Becker GJ
Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214
[TBL] [Abstract][Full Text] [Related]
19. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.
Kohzuki M; Kanazawa M; Liu PF; Kamimoto M; Yoshida K; Saito T; Yasujima M; Sato T; Abe K
J Hypertens; 1995 Dec; 13(12 Pt 2):1785-90. PubMed ID: 8903652
[TBL] [Abstract][Full Text] [Related]
20. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
